Nucleozin
Modify Date: 2024-01-09 08:20:38
Nucleozin structure
|
Common Name | Nucleozin | ||
|---|---|---|---|---|
| CAS Number | 341001-38-5 | Molecular Weight | 426.85300 | |
| Density | 1.371 | Boiling Point | 673.8ºC at 760 mmHg | |
| Molecular Formula | C21H19ClN4O4 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 361.3ºC | |
| Symbol |
GHS06 |
Signal Word | Danger | |
Use of NucleozinNucleozin targets influenza A nucleoprotein (NP), a multifunctional, RNA-binding protein necessary for virus replication. IC50 Value: Target: Influenza Virus NPNucleozin targets influenza A nucleoprotein, a multifunctional, RNA-binding protein necessary for virus replication. It induces the formation of nucleoptotein aggregates and inhibits its accumulation, interfering with viral replication. EC50 is in the nM range. Nucleozin is effective in H1N1, H3N2, and H5N1 flu virus strains. |
| Name | [4-(2-chloro-4-nitrophenyl)piperazin-1-yl]-(5-methyl-3-phenyl-1,2-oxazol-4-yl)methanone |
|---|---|
| Synonym | More Synonyms |
| Description | Nucleozin targets influenza A nucleoprotein (NP), a multifunctional, RNA-binding protein necessary for virus replication. IC50 Value: Target: Influenza Virus NPNucleozin targets influenza A nucleoprotein, a multifunctional, RNA-binding protein necessary for virus replication. It induces the formation of nucleoptotein aggregates and inhibits its accumulation, interfering with viral replication. EC50 is in the nM range. Nucleozin is effective in H1N1, H3N2, and H5N1 flu virus strains. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.371 |
|---|---|
| Boiling Point | 673.8ºC at 760 mmHg |
| Molecular Formula | C21H19ClN4O4 |
| Molecular Weight | 426.85300 |
| Flash Point | 361.3ºC |
| Exact Mass | 426.10900 |
| PSA | 95.40000 |
| LogP | 4.70010 |
| Index of Refraction | 1.631 |
| Storage condition | 2-8℃ |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H301 |
| Precautionary Statements | P301 + P310 |
| RIDADR | UN 2811 6.1 / PGIII |
|
~74%
Nucleozin CAS#:341001-38-5 |
| Literature: VIRONOVA AB; HOMMAN, Mohammed; KINGI, Ngarita; BERGMAN, Jan; ENGQVIST, Robert Patent: WO2013/171334 A1, 2013 ; Location in patent: Page/Page column 23 ; |
|
~43%
Nucleozin CAS#:341001-38-5 |
| Literature: The University of Hong Kong Patent: US2011/212975 A1, 2011 ; Location in patent: Page/Page column 14; 18 ; |
|
~%
Nucleozin CAS#:341001-38-5 |
| Literature: WO2011/15037 A1, ; |
|
~%
Nucleozin CAS#:341001-38-5 |
| Literature: WO2011/15037 A1, ; |
|
~%
Nucleozin CAS#:341001-38-5 |
| Literature: WO2011/15037 A1, ; |
|
~%
Nucleozin CAS#:341001-38-5 |
| Literature: WO2011/15037 A1, ; US2011/212975 A1, ; |
|
~%
Nucleozin CAS#:341001-38-5 |
| Literature: WO2013/171334 A1, ; |
|
A GFP-tagged nucleoprotein-based aggregation assay for anti-influenza drug discovery and antibody development.
Analyst 138(20) , 6073-80, (2013) Influenza is a viral pandemic that affects millions of people worldwide. Seasonal variations due to genetic shuffling and antigenic drifts in the influenza viruses have necessitated continual updating... |
| Nucleozin| |
| (4-(2-chloro-4-nitrophenyl)piperazin-1-yl)(5-methyl-3-phenylisoxazol-4-yl)methanone |
| [4-(2-chloro-4-nitrophenyl)piperazin-1-yl]-[3-phenyl-5-methylisoxazol-4-yl]methanone |
| Nucleozin |